191 related articles for article (PubMed ID: 9816323)
41. The effect of leucovorin on the therapeutic index of fluorouracil in cancer patients.
DeLap RJ
Yale J Biol Med; 1988; 61(1):23-34. PubMed ID: 3284210
[TBL] [Abstract][Full Text] [Related]
42. A phase I study of 5-fluorouracil, leucovorin and levamisole.
Cleary JF; Arzoomanian R; Alberti D; Feierabend C; Storer B; Witt P; Carbone P; Wilding G
Cancer Chemother Pharmacol; 1997; 39(4):300-6. PubMed ID: 9025770
[TBL] [Abstract][Full Text] [Related]
43. Leucovorin modulation of 5-iododeoxyuridine radiosensitization: a phase I study.
McGinn CJ; Kunugi KA; Tutsch KD; Feierabend C; Alberti D; Lindstrom MJ; Wilding G; Arzoomanian RZ; Kinsella TJ
Clin Cancer Res; 1996 Aug; 2(8):1299-305. PubMed ID: 9816300
[TBL] [Abstract][Full Text] [Related]
44. Weekly chronomodulated 48 h infusion of high-dose 5-fluorouracil modulated by methotrexate and (6S)-leucovorin in advanced colorectal cancer: a phase IB study.
Punt CJ; Kamm YL; Wagener DJ
Anticancer Drugs; 1997 Jun; 8(5):454-8. PubMed ID: 9215607
[TBL] [Abstract][Full Text] [Related]
45. Sequence-dependent toxicity profile in modified FAMTX (fluorouracil-adriamycin-methotrexate) chemotherapy with lenograstim support for advanced gastric cancer: a feasibility study.
Westermann AM; Taal BG; Swart M; Boot H; Craanen M; Gerritsen WR
Pharmacol Res; 2000 Aug; 42(2):151-6. PubMed ID: 10887044
[TBL] [Abstract][Full Text] [Related]
46. Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma.
Schwarz LR
Cancer; 1996 Aug; 78(3):566-7. PubMed ID: 8697406
[No Abstract] [Full Text] [Related]
47. Phase I/II study of cyclophosphamide, doxorubicin, fluorouracil, and leucovorin for treatment of metastatic adenocarcinoma.
Parnes HL; Abrams JS; Tait N; Minford J; Allen SL; Duggan D; Aisner J
J Natl Cancer Inst; 1991 Jul; 83(14):1017-20. PubMed ID: 2072408
[TBL] [Abstract][Full Text] [Related]
48. High-dose edatrexate with oral leucovorin rescue: a phase I and clinical pharmacological study in adults with advanced cancer.
Pisters KM; Tyson LB; Tong W; Fleisher M; Miller VA; Grant SC; Pfister DG; Rigas JR; Densmore CL; Krol G; Heelan RT; Sirotnak FM; Bertino JR; Kris MG
Clin Cancer Res; 1996 Nov; 2(11):1819-24. PubMed ID: 9816135
[TBL] [Abstract][Full Text] [Related]
49. Intensified bimonthly cisplatin with bolus 5-fluorouracil, continuous 5-fluorouracil and high-dose leucovorin (LV5FU2) in Patients with advanced gastrointestinal carcinomas: a phase I dose-finding and pharmacokinetic study.
Bamias A; Syrigos K; Fountzilas G; Tzamakou E; Soulti K; Karavasilis V; Alamanos Y; Christodoulou C; Pavlidis N
Am J Clin Oncol; 2004 Oct; 27(5):465-71. PubMed ID: 15596912
[TBL] [Abstract][Full Text] [Related]
50. Phase I trial of metoprine in patients with advanced cancer.
Currie VE; Kempin SJ; Young CW
Cancer Treat Rep; 1980; 64(8-9):951-6. PubMed ID: 6969632
[TBL] [Abstract][Full Text] [Related]
51. Phase I-II trial of high-dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer.
Madajewicz S; Petrelli N; Rustum YM; Campbell J; Herrera L; Mittelman A; Perry A; Creaven PJ
Cancer Res; 1984 Oct; 44(10):4667-9. PubMed ID: 6331882
[TBL] [Abstract][Full Text] [Related]
52. Phase II trial of 5-fluorouracil, folinic acid and recombinant alpha-2a-interferon in patients with advanced colorectal cancer.
Ravandi F; Rytting ME; Osmon C; Braud EL; Roach RW; Edwards K; Winn R; Abbruzzese JL; Pazdur R
Anticancer Drugs; 1999 Jul; 10(6):519-24. PubMed ID: 10885898
[TBL] [Abstract][Full Text] [Related]
53. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer.
Poon MA; O'Connell MJ; Wieand HS; Krook JE; Gerstner JB; Tschetter LK; Levitt R; Kardinal CG; Mailliard JA
J Clin Oncol; 1991 Nov; 9(11):1967-72. PubMed ID: 1941055
[TBL] [Abstract][Full Text] [Related]
54. Weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas.
Chen JS; Jan YY; Lin YC; Wang HM; Chang WC; Liau CT
Anticancer Drugs; 1998 Jun; 9(5):393-7. PubMed ID: 9660535
[TBL] [Abstract][Full Text] [Related]
55. A phase II trial of continuous infusion cisplatin and 5-fluorouracil with oral calcium leucovorin in colorectal carcinoma.
Posner M; Martin A; Slapak CA; Clark JW; Cummings FJ; Robert NJ; Sikov W; Akerley W
Am J Clin Oncol; 1992 Jun; 15(3):239-41. PubMed ID: 1590278
[TBL] [Abstract][Full Text] [Related]
56. Multimodal biochemical modulation of 5-fluorouracil by leucovorin, methotrexate, and interferon alpha in patients with advanced colorectal cancer.
Cascinu S; Alessandroni P; Rossi D; Del Ferro E; Fedeli A; Casadei V; Catalano G
Cancer Chemother Pharmacol; 1996; 38(4):385-6. PubMed ID: 8674163
[TBL] [Abstract][Full Text] [Related]
57. 5-Fluorouracil/Leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma: a clinical experience.
Podolsky L; Oh M; Subbarayan PR; Francheschi D; Livingstone A; Ardalan B
Acta Oncol; 2011 May; 50(4):602-5. PubMed ID: 20950119
[No Abstract] [Full Text] [Related]
58. Phase I study of 5-fluorouracil with folinic acid combined with recombinant human granulocyte-macrophage colony-stimulating factor.
Moore DF; Pazdur R
Am J Clin Oncol; 1992 Dec; 15(6):464-6. PubMed ID: 1449107
[TBL] [Abstract][Full Text] [Related]
59. 5-Fluorouracil dose intensity increase in 5-fluorouracil and leucovorin combination: results of a phase II study.
Cascinu S; Fedeli A; Luzi Fedeli S; Catalano G
J Chemother; 1991 Feb; 3(1):51-4. PubMed ID: 2019864
[TBL] [Abstract][Full Text] [Related]
60. Subcutaneous granulocyte-macrophage colony-stimulating factor in mucositis induced by an adjuvant 5-fluorouracil plus leucovorin regimen. A phase II study and review of the literature.
Rossi A; Rosati G; Colarusso D; Manzione L
Oncology; 2003; 64(4):353-60. PubMed ID: 12759532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
